TrialInvestigational new drugs2018

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

Sandra P D'Angelo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.